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of dyslipidemia in Indian subjects: Our perspectiveDear Editor,
We read with interest the commentary by Enas A. Enas and
colleagues1 on the recently published Consensus Statement
on Management of Dyslipidemia in Indian Subjects (CSMDIS)2
and thank them for their insightful comments. It is heartening
to see that the document has generated such interest and has
drawn attention of such world-renowned leaders in the ﬁeld of
lipid management.
We are in agreement with many of the observations made
by Enas A. Enas and colleagues about the current understand-
ing of the role of statin therapy in reducing cardiovascular (CV)
morbidity and mortality. As highlighted by them, there is
unequivocal evidence to show that statins are currently the
most powerful pharmacological agents available to reduce CV
risk. More importantly, the beneﬁcial effects of statins are
observed in direct proportion to the baseline CV risk and occur
regardless of the low-density lipoprotein cholesterol (LDLC)
levels. Accordingly, most guidelines today recommend initi-
ating statin therapy based on the estimated CV risk rather than
the absolute LDLC levels. We also agree that there is now
increasing data to suggest that lifetime CV risk may be a more
appropriate metric, rather than the short-term (i.e. 10-years)
CV risk, for guiding management decisions in primaryprevention of CV disease, particularly in young individuals.
However, we wish to emphasize that there is currently no
validated risk assessment tool available for estimating short-
term or lifetime CV risk in Indians. The risk assessment
algorithm proposed by the International Atherosclerosis
Society (IAS)3 is simple to use but its use in Indians has
practical limitations, as highlighted below. In addition, we also
notice that the interpretation by Enas A. Enas et al. of the
recommendations for initiating statin therapy is different
from what has actually been proposed in the CSMDIS. We
discuss below these issues in greater detail.
1. IAS algorithm for estimation of lifetime CV
risk
The algorithm proposed by the IAS for estimating lifetime CV
risk was ﬁrst developed by Lloyd-Jones et al. based on the
Framingham study data.4 This algorithm considers only four
risk factors – diabetes, smoking, systolic blood pressure (SBP),
and total cholesterol (TC). Both diabetes and smoking are
considered to be major risk factors, whereas SBP and TC are
graded as minor, moderate, and major risk factors depending
on the actual levels (SBP: minor – 120–139 mmHg, moderate –
140–159 mmHg, and major – >160 mmHg; TC: minor – 180–
199 mg/dL, moderate – 200–239 mg/dL, and major – >240 mg/
dL). Based on the number of minor, moderate, and major risk
factors, lifetime CV risk can be estimated in any individual. For
nonwhites, the IAS document also provides appropriate
ethnic-speciﬁc calibration factors in order to derive more
accurate risk estimates in different population groups. Thus,
IAS risk algorithm is simple to use, does not require elaborate
laboratory testing, and is well suited for clinic-based estima-
tion of CV risk.
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Indian subjects has important practical limitations. According
to the IAS algorithm, any male subject who has just one minor
risk factor is considered to have 25% lifetime risk of CV events.
Since the calibration factor for urban Indians is 1.8, this
translates in to 45% risk of CV events, which is the threshold
for deﬁning high risk. Thus, every urban Indian man with even
SBP marginally above 120 mmHg or TC above 180 mg/dL and
no other CV risk factor at all will be designated as having high
CV risk. To put this in perspective, let us consider an example
of a 40-year old urban Indian man who is free from any CV
disease. He is nondiabetic, nonsmoker, nonhypertensive, and
does not have any family history of premature CV disease. His
blood pressure is 122/80 mmHg and his TC is 170 mg/dL. Most
readers will agree that this person seems to be in reasonably
good state of health and only needs general advice about
healthy lifestyle. However, the IAS risk algorithm will identify
this individual as being at high risk, and therefore, a candidate
for lifelong high-intensity statin therapy! Thus, it is evident
that the IAS risk algorithm, in its present form, will identify
almost every urban Indian man as being at 'high-risk,' which
defeats the very purpose of using a risk estimation tool.
Further, even if it was agreed that all such men were at high
lifetime risk of having a vascular event, the appropriateness of
using this risk estimate to recommend life-long, high-
intensity statin therapy in all these individuals remains highly
controversial.
Another challenge with the IAS risk algorithm is that it is
based on the data derived from individuals above 50 years of
age, and therefore, is ideally applicable to these individuals
only. Using this algorithm in younger individuals can lead to
unwarranted discrepancies since age is not included as one of
the risk factors. For example, if we have another urban Indian
male who is 55 years of age and has the same risk proﬁle as the
younger individual in the above illustration but has BP 118/
80 mmHg, he will be considered to be at low risk of CV events
as per the IAS risk algorithm. This again seems to be
counterintuitive.
2. Deﬁnition of 'high-risk' and the threshold
for initiating statin therapy
The concept of classifying patients into high-, intermediate-
and low-risk based on 10-year risk estimates, and matching
intensity of lipid-lowering treatment with the estimated CV
risk was ﬁrst propounded by the National Cholesterol
Education Program expert panel on detection, evaluation,
and treatment of high blood cholesterol in adults (Adult
Treatment Panel III).5 The 'high-risk' was deﬁned as >20%
risk of hard coronary heart disease (CHD) events over the next
10 years. This risk level was believed to be similar to that
anticipated in a patient who already had evidence of
atherosclerotic vascular disease. Accordingly, 'high-risk'
category was designated as 'coronary artery disease risk
equivalent,' and treatment strategy similar to that used for
secondary prevention was recommended for this group of
patients.
Since then, numerous guidelines have adopted this
approach but have used different cut-off values to deﬁne'high-risk'. Although most deﬁnitions have hovered around
the same threshold of >20%, the use of lower thresholds for
initiating statin therapy (in primary prevention setting) by
some of the recent guidelines seems to have caused confusion.
In this context, it is important to note that the 'high CV risk'
may not necessarily be same as 'risk high enough' to warrant
statin therapy. Statins are known to reduce CV events even in
patients who are at much lower level of CV risk. The thresholds
proposed by these guidelines are only the levels beyond which
there is clear beneﬁt of statin therapy but do not attempt to
redeﬁne 'high CV risk'. In fact, if the term 'high-risk' is
expected to convey 'CV disease risk equivalent' status, there is
little justiﬁcation for signiﬁcantly lowering the threshold for
deﬁning 'high-risk'. This understanding is corroborated by the
following observations:
 National Lipid Association guidelines (October 2014) clearly
mention that using the pooled cohort equation, 'high-risk,'
should be deﬁned as 10-year risk >15%.6
 In primary prevention setting, the NICE guidelines (July
2014) recommend only 20 mg atorvastatin/day for people
>10% risk, unlike much higher doses (80 mg atorvastatin)
recommended for secondary prevention.7 This suggests that
>10% risk over 10 years is not perceived as truly high-risk,
but only a threshold to warrant statin therapy.
 Canadian guidelines (Feb 2013) used a cut-off of 20% to
deﬁne high risk.3
 Australian guidelines (May 2012) used a cut-off of 15% over 5
years (equivalent to >30% over 10 years) to deﬁne high risk.3
 World Health Organization risk prediction charts also use
>20% 10-year risk as the deﬁnition for high risk.8
However, regardless of what deﬁnition is used for
deﬁning high CV risk, there is ample evidence to suggest
that statin therapy is beneﬁcial even in individuals at much
lower risk of vascular events. Accordingly, the recently
published American College of Cardiology/American
Heart Association (ACC/AHA) guidelines recommend statin
therapy in all individuals with >7.5% 10-year risk of CV
events, with an option to use statin therapy even in those
with 5–7.5% CV risk.9
Contrary to the perception by Enas A. Enas and colleagues,
the present Indian consensus document does not restrict use
of statins only to individuals with >20% 10-year risk. The
document clearly recommends statin therapy for all individ-
uals having 10-year risk >10%, regardless of the baseline LDLC
levels and without the need to wait for the effect of lifestyle
interventions. Further, even in those with <10% risk (which
means everyone else other than those with >10% risk), statin
therapy is recommended if LDLC is persistently above 130 mg/
dL despite adequate lifestyle modiﬁcation. These recommen-
dations are in agreement with most of the latest guidelines,
including those of the ACC/AHA. In contrast, the IAS guidelines
only mention that lipid-lowering drug therapy should be
considered (and do not make it mandatory) in those who are
at moderately high CV risk. The Indian recommendation of statin
therapy in all individuals (even if their 10-year CV risk is <10%)
with LDLC >130 mg/dL despite adequate lifestyle measures also
addresses, to a great extent, the issue of young individuals having
low short-term risk despite a high lifetime CV risk.
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has proposed a hybrid approach for lipid management,
combining 'LDLC goal-based strategy' with the one based on
the magnitude of LDLC reduction, even though this was in
stark contrast with the ACC/AHA recommendations. It was
recommended that once initiated, the aim of the
statin therapy should be to lower LDLC by at least 50% (i.e.
high-intensity therapy) in those at high CV risk or those
with established atherosclerotic vascular disease and by at
least 30–50% (i.e. moderate-intensity therapy) in all the other
subjects. It is heartening to note that these recommendations
have been fully supported by the recent National Lipid
Association recommendations, which were published at a
time when the Indian consensus document was already in
print.6
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